查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1265702

阵发性夜间血尿症(PNH)治疗的全球市场

Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment
出版日期: | 出版商: Global Industry Analysts, Inc. | 英文 93 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

阵发性夜间血尿症(PNH)治疗的全球市场在2030年前将达到75亿美元

在COVID-19后改变的商务环境中，2022年28亿美元的阵发性夜间血尿症(PNH)治疗的全球市场，2030年之前达到75亿美元的规模，在2022年～2030年预计将以年复合成长率13.1％增长。本报告所分析之市场区隔之一的医药品年复合成长率将记录11％，到分析期间结束时将达到49亿美元。考虑疫情后的復苏，其他治疗领域今后8年的年复合成长率将修正为18.3％。

美国市场估算为8亿1,670万美元，中国则将以年复合成长率12.6％的速度成长。

美国的阵发性夜间血尿症(PNH)治疗市场在2022年估算为8亿1,670万美元。作为世界第2大经济大国的中国，在2022年～2030年年复合成长率预计将为12.6％，在2030年达到13亿美元的市场规模。其他热门的地区市场有日本和加拿大，在2022年～2030年预计将各以11％，11％的速度成长。在欧洲市场中，德国以年复合成长率9.3％成长。

调查对像企业范例

  • Achillion Pharmaceuticals
  • Akari Therapeutics
  • Alexion Pharmaceuticals
  • Amgen Inc.
  • Apellis Pharmaceuticals
  • F. Hoffmann-La Roche AG.
  • GE Healthcare
  • Johnson & Johnson
  • Ra Pharmaceuticals
  • Regeneron Pharmaceuticals, Inc.
  • Takeda Pharmaceutical Company Limited(Shire Plc)
  • Thermo Fisher Scientific Inc.

目录

第1章 调查手法

第2章 摘要整理

  • 市场概要
  • 主要企业
  • 市场趋势与推动因素
  • 全球市场预测

第3章 市场分析

  • 美国
  • 加拿大
  • 日本
  • 中国
  • 欧洲
  • 法国
  • GERMANY
  • itariya
  • 英国
  • 其他欧洲
  • 亚太地区
  • 全球其他地区

第4章 竞争

简介目录
Product Code: MCP22462

What`s New for 2023?

»Special coverage on Russia-Ukraine war; global inflation; easing of "zero-Covid" policy in China and its `bumpy` reopening; supply chain disruptions, global trade tensions; and risk of recession.

»Global competitiveness and key competitor percentage market shares

» Market presence across multiple geographies - Strong/Active/Niche/Trivial

»Online interactive peer-to-peer collaborative bespoke updates

»Access to our digital archives and MarketGlass Research Platform

»Complimentary updates for one year

Looking Ahead to 2023

The global economy is at a critical crossroads with a number of interlocking challenges and crises running in parallel. The uncertainty around how Russia`s war on Ukraine will play out this year and the war`s role in creating global instability means that the trouble on the inflation front is not over yet. Food and fuel inflation will remain a persistent economic problem. Higher retail inflation will impact consumer confidence and spending. As governments combat inflation by raising interest rates, new job creation will slowdown and impact economic activity and growth. Lower capital expenditure is in the offing as companies go slow on investments, held back by inflation worries and weaker demand. With slower growth and high inflation, developed markets seem primed to enter into a recession. Fears of new COVID outbreaks and China's already uncertain post-pandemic path poses a real risk of the world experiencing more acute supply chain pain and manufacturing disruptions this year. Volatile financial markets, growing trade tensions, stricter regulatory environment and pressure to mainstream climate change into economic decisions will compound the complexity of challenges faced. Year 2023 is expected to be tough year for most markets, investors and consumers. Nevertheless, there is always opportunity for businesses and their leaders who can chart a path forward with resilience and adaptability.

Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market to Reach $7.5 Billion by 2030

In the changed post COVID-19 business landscape, the global market for Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment estimated at US$2.8 Billion in the year 2022, is projected to reach a revised size of US$7.5 Billion by 2030, growing at aCAGR of 13.1% over the period 2022-2030. Medication, one of the segments analyzed in the report, is projected to record 11% CAGR and reach US$4.9 Billion by the end of the analysis period. Taking into account the ongoing post pandemic recovery, growth in the Other Treatments segment is readjusted to a revised 18.3% CAGR for the next 8-year period.

The U.S. Market is Estimated at $816.7 Million, While China is Forecast to Grow at 12.6% CAGR

The Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment market in the U.S. is estimated at US$816.7 Million in the year 2022. China, the world`s second largest economy, is forecast to reach a projected market size of US$1.3 Billion by the year 2030 trailing a CAGR of 12.6% over the analysis period 2022 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 11% and 11% respectively over the 2022-2030 period. Within Europe, Germany is forecast to grow at approximately 9.3% CAGR.

Select Competitors (Total 42 Featured) -

  • Achillion Pharmaceuticals
  • Akari Therapeutics
  • Alexion Pharmaceuticals
  • Amgen Inc.
  • Apellis Pharmaceuticals
  • F. Hoffmann-La Roche AG.
  • GE Healthcare
  • Johnson & Johnson
  • Ra Pharmaceuticals
  • Regeneron Pharmaceuticals, Inc.
  • Takeda Pharmaceutical Company Limited (Shire Plc)
  • Thermo Fisher Scientific Inc.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Impact of Covid-19 and a Looming Global Recession
    • Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment - Global Key Competitors Percentage Market Share in 2022 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2022 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Recent Past, Current & Future Analysis for Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 2: World Historic Review for Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 3: World 16-Year Perspective for Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2014, 2023 & 2030
    • TABLE 4: World Recent Past, Current & Future Analysis for Medication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 5: World Historic Review for Medication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 6: World 16-Year Perspective for Medication by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030
    • TABLE 7: World Recent Past, Current & Future Analysis for Other Treatments by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 8: World Historic Review for Other Treatments by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 9: World 16-Year Perspective for Other Treatments by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030
    • TABLE 10: World Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2023 (E)
    • TABLE 11: USA Recent Past, Current & Future Analysis for Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment by Treatment - Medication and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 12: USA Historic Review for Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment by Treatment - Medication and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 13: USA 16-Year Perspective for Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment by Treatment - Percentage Breakdown of Value Sales for Medication and Other Treatments for the Years 2014, 2023 & 2030
  • CANADA
    • TABLE 14: Canada Recent Past, Current & Future Analysis for Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment by Treatment - Medication and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 15: Canada Historic Review for Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment by Treatment - Medication and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 16: Canada 16-Year Perspective for Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment by Treatment - Percentage Breakdown of Value Sales for Medication and Other Treatments for the Years 2014, 2023 & 2030
  • JAPAN
    • Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2023 (E)
    • TABLE 17: Japan Recent Past, Current & Future Analysis for Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment by Treatment - Medication and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 18: Japan Historic Review for Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment by Treatment - Medication and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 19: Japan 16-Year Perspective for Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment by Treatment - Percentage Breakdown of Value Sales for Medication and Other Treatments for the Years 2014, 2023 & 2030
  • CHINA
    • Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2023 (E)
    • TABLE 20: China Recent Past, Current & Future Analysis for Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment by Treatment - Medication and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 21: China Historic Review for Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment by Treatment - Medication and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 22: China 16-Year Perspective for Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment by Treatment - Percentage Breakdown of Value Sales for Medication and Other Treatments for the Years 2014, 2023 & 2030
  • EUROPE
    • Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2023 (E)
    • TABLE 23: Europe Recent Past, Current & Future Analysis for Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 24: Europe Historic Review for Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 25: Europe 16-Year Perspective for Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2014, 2023 & 2030
    • TABLE 26: Europe Recent Past, Current & Future Analysis for Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment by Treatment - Medication and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 27: Europe Historic Review for Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment by Treatment - Medication and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 28: Europe 16-Year Perspective for Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment by Treatment - Percentage Breakdown of Value Sales for Medication and Other Treatments for the Years 2014, 2023 & 2030
  • FRANCE
    • Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2023 (E)
    • TABLE 29: France Recent Past, Current & Future Analysis for Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment by Treatment - Medication and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 30: France Historic Review for Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment by Treatment - Medication and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 31: France 16-Year Perspective for Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment by Treatment - Percentage Breakdown of Value Sales for Medication and Other Treatments for the Years 2014, 2023 & 2030
  • GERMANY
    • Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2023 (E)
    • TABLE 32: Germany Recent Past, Current & Future Analysis for Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment by Treatment - Medication and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 33: Germany Historic Review for Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment by Treatment - Medication and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 34: Germany 16-Year Perspective for Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment by Treatment - Percentage Breakdown of Value Sales for Medication and Other Treatments for the Years 2014, 2023 & 2030
  • ITALY
    • TABLE 35: Italy Recent Past, Current & Future Analysis for Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment by Treatment - Medication and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 36: Italy Historic Review for Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment by Treatment - Medication and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 37: Italy 16-Year Perspective for Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment by Treatment - Percentage Breakdown of Value Sales for Medication and Other Treatments for the Years 2014, 2023 & 2030
  • UNITED KINGDOM
    • Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2023 (E)
    • TABLE 38: UK Recent Past, Current & Future Analysis for Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment by Treatment - Medication and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 39: UK Historic Review for Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment by Treatment - Medication and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 40: UK 16-Year Perspective for Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment by Treatment - Percentage Breakdown of Value Sales for Medication and Other Treatments for the Years 2014, 2023 & 2030
  • REST OF EUROPE
    • TABLE 41: Rest of Europe Recent Past, Current & Future Analysis for Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment by Treatment - Medication and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 42: Rest of Europe Historic Review for Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment by Treatment - Medication and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 43: Rest of Europe 16-Year Perspective for Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment by Treatment - Percentage Breakdown of Value Sales for Medication and Other Treatments for the Years 2014, 2023 & 2030
  • ASIA-PACIFIC
    • Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2023 (E)
    • TABLE 44: Asia-Pacific Recent Past, Current & Future Analysis for Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment by Treatment - Medication and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 45: Asia-Pacific Historic Review for Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment by Treatment - Medication and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 46: Asia-Pacific 16-Year Perspective for Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment by Treatment - Percentage Breakdown of Value Sales for Medication and Other Treatments for the Years 2014, 2023 & 2030
  • REST OF WORLD
    • TABLE 47: Rest of World Recent Past, Current & Future Analysis for Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment by Treatment - Medication and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 48: Rest of World Historic Review for Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment by Treatment - Medication and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 49: Rest of World 16-Year Perspective for Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment by Treatment - Percentage Breakdown of Value Sales for Medication and Other Treatments for the Years 2014, 2023 & 2030

IV. COMPETITION